Drug intelligence / Profile preview

OPC-214870

Development stage: Phase 1
Lead developer: Otsuka Pharmaceutical Development & Commercialization
Modality: Small Molecules
Administration: Oral

Overview

OPC-214870 is an orally bioavailable small molecule drug under development by Otsuka Pharmaceutical for the treatment of epilepsy and seizure disorders. Its precise mechanism of action has not been fully elucidated, but it is being investigated as a potential antiepileptic agent. Clinical studies have evaluated its pharmacodynamics and pharmacokinetics in healthy volunteers, with ongoing trials assessing its efficacy in patients with epilepsy. The drug represents a novel approach to address unmet needs in patients whose seizures are not adequately controlled by existing antiepileptic drugs[1][2][3][4][5].

Beyond the preview

Go deeper on OPC-214870.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OPC-214870.

Explore the full profile